Lilly Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and five approved drugs.
There is one US patent protecting LILLY drugs.
There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-seven supplementary protection certificates in thirteen countries.
Summary for Lilly
| International Patents: | 30 |
| US Patents: | 1 |
| Tradenames: | 85 |
| Ingredients: | 81 |
| NDAs: | 105 |
Drugs and US Patents for Lilly
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | CECLOR | cefaclor | CAPSULE;ORAL | 050521-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | ONCOVIN | vincristine sulfate | INJECTABLE;INJECTION | 014103-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-003 | Nov 26, 2002 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Lilly | GLUCAGON | glucagon hydrochloride | INJECTABLE;INJECTION | 012122-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | GLUCAGON | glucagon hydrochloride | INJECTABLE;INJECTION | 012122-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | CECLOR | cefaclor | FOR SUSPENSION;ORAL | 050522-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Lilly | HISTAMINE PHOSPHATE | histamine phosphate | INJECTABLE;INJECTION | 000734-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lilly
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-004 | Jan 7, 2008 | 6,140,329 | ⤷ Subscribe |
| Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | 5,457,117 | ⤷ Subscribe |
| Lilly | ONCOVIN | vincristine sulfate | INJECTABLE;INJECTION | 014103-003 | Mar 7, 1984 | 4,619,935 | ⤷ Subscribe |
| Lilly | STRATTERA | atomoxetine hydrochloride | CAPSULE;ORAL | 021411-008 | Feb 14, 2005 | 5,658,590*PED | ⤷ Subscribe |
| Lilly | CIALIS | tadalafil | TABLET;ORAL | 021368-003 | Nov 21, 2003 | 6,140,329 | ⤷ Subscribe |
| Lilly | GEMZAR | gemcitabine hydrochloride | INJECTABLE;INJECTION | 020509-001 | May 15, 1996 | 5,464,826*PED | ⤷ Subscribe |
| Lilly | ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462-002 | Sep 7, 2007 | 5,217,974*PED | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LILLY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | ➤ Subscribe | 2008-08-04 |
| ➤ Subscribe | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | ➤ Subscribe | 2007-05-29 |
| ➤ Subscribe | Capsules | 3 mg/25 mg | ➤ Subscribe | 2008-05-08 |
| ➤ Subscribe | For Injection | 1g/vial | ➤ Subscribe | 2005-11-14 |
| ➤ Subscribe | For Injection | 100 mg/vial | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | For Injection | 1000 mg/vial | ➤ Subscribe | 2012-06-27 |
| ➤ Subscribe | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | ➤ Subscribe | 2015-07-27 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg and 20 mg | ➤ Subscribe | 2007-11-21 |
| ➤ Subscribe | Delayed-release Capsules | 40 mg | ➤ Subscribe | 2012-05-10 |
| ➤ Subscribe | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | ➤ Subscribe | 2005-01-10 |
| ➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2005-11-01 |
| ➤ Subscribe | For Injection | 2 g/vial | ➤ Subscribe | 2007-08-24 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-02-04 |
| ➤ Subscribe | For Injection | 750 mg/vial | ➤ Subscribe | 2016-10-06 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2008-10-14 |
International Patents for Lilly Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 177829 | ⤷ Subscribe |
| Portugal | 1732629 | ⤷ Subscribe |
| Eurasian Patent Organization | 200601801 | ⤷ Subscribe |
| New Zealand | 549099 | ⤷ Subscribe |
| South Korea | 100763051 | ⤷ Subscribe |
| Eurasian Patent Organization | 009497 | ⤷ Subscribe |
| South Africa | 200606885 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lilly Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0584952 | 980044 | Netherlands | ⤷ Subscribe | PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001 |
| 0705275 | C300021 | Netherlands | ⤷ Subscribe | PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 1480644 | 2016C/069 | Belgium | ⤷ Subscribe | PRODUCT NAME: ZAVICEFTA (COMBINAISON DE CEFTAZIDIME ET AVIBACTAM); AUTHORISATION NUMBER AND DATE: EU/1/16/1109/001 20160628 |
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| 2957286 | 300962 | Netherlands | ⤷ Subscribe | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721 |
| 1280520 | 14/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
